Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer
| العنوان: | Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer |
|---|---|
| المؤلفون: | Shota Omori, Haruki Kobayashi, Eriko Miyawaki, Masahiro Endo, Tateaki Naito, Hirotsugu Kenmotsu, Takahisa Kawamura, Kazuhisa Nakashima, Keita Mori, Kazushige Wakuda, Akira Ono, Toshiaki Takahashi, Haruyasu Murakami, Taichi Miyawaki, Nobuaki Mamesaya |
| المصدر: | In Vivo. 33:2229-2234 |
| بيانات النشر: | Anticancer Research USA Inc., 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Kaplan-Meier Estimate, macromolecular substances, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, Relapsed Small Cell Lung Cancer, Etoposide, Aged, Retrospective Studies, Pharmacology, Cisplatin, Chemotherapy, business.industry, Medical record, technology, industry, and agriculture, Middle Aged, Prognosis, Small Cell Lung Carcinoma, Irinotecan, Treatment Outcome, 030220 oncology & carcinogenesis, Retreatment, Female, business, Amrubicin, Research Article, medicine.drug |
| الوصف: | Background/aim To evaluate treatment efficacy of cisplatin, etoposide, and irinotecan combined therapy (PEI), platinum-rechallenge chemotherapy (Pt-Re) and amrubicin monotherapy (AMR) for patients with sensitive relapsed small cell lung cancer (SCLC). Patients and methods We defined sensitive relapse as treatment-free interval (TFI) ≥90 days. We retrospectively collected patients' data from medical records between September 2002 and December 2016. Patients with sensitive relapsed SCLC who received second-line chemotherapy were separated into those treated with PEI, with Pt-Re, or with AMR. Results Seventy-one patients (16 PEI group, 27 Pt-Re group, and 28 AMR group) were assessable for efficacy. No significant differences in patient characteristics were found among the three groups. The median overall survival (MST) was 29.3 months in the PEI group, 24.6 months in the Pt-Re group, and 20.6 months in the AMR group (p=0.042). Conclusion A significant difference was observed in the overall survival of patients treated with PEI, Pt-Re and AMR and the MST of PEI was the longest. |
| تدمد: | 1791-7549 0258-851X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05493836eed27c7e45cb60ed873b7b20Test https://doi.org/10.21873/invivo.11727Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....05493836eed27c7e45cb60ed873b7b20 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17917549 0258851X |
|---|